R
Rodrigo Dienstmann
Researcher at Autonomous University of Barcelona
Publications - 104
Citations - 7094
Rodrigo Dienstmann is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 28, co-authored 61 publications receiving 5168 citations. Previous affiliations of Rodrigo Dienstmann include Universidade Federal do Rio Grande do Sul & Sage Bionetworks.
Papers
More filters
Journal ArticleDOI
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more
TL;DR: An international consortium dedicated to large-scale data sharing and analytics across expert groups is formed, showing marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features.
Journal ArticleDOI
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Rodrigo Dienstmann,Louis Vermeulen,Justin Guinney,Scott Kopetz,Sabine Tejpar,Josep Tabernero +5 more
TL;DR: Better characterization of the transcriptomic subtypes of colorectal cancer, encompassing tumour, stromal and immune components, has revealed convergent pathway dependencies that mandate a 'multi-molecular' perspective for the development of therapies to treat this disease.
Journal ArticleDOI
Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
TL;DR: B biomarker analyses of multiple studies strongly support the feasibility of refining risk stratification in colon cancer by factoring in molecular characteristics with pathologic tumor staging, and the value of BRAF or KRAS mutations as additional risk factors in stage III disease is greater when microsatellite status and tumor location are taken into account.
Journal ArticleDOI
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Frank A. Sinicrope,Qian Shi,Thomas C. Smyrk,Stephen N. Thibodeau,Rodrigo Dienstmann,Justin Guinney,Brian M. Bot,Sabine Tejpar,Mauro Delorenzi,Richard M. Goldberg,Michelle R. Mahoney,Daniel J. Sargent,Steven R. Alberts +12 more
TL;DR: Subtypes of stage III colon cancer, based on detection of mutations in BRAF (V600E) or KRAS, and MMR status that show differences in clinical and pathologic features and disease-free survival are identified.
Journal ArticleDOI
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
David Tamborero,Carlota Rubio-Perez,Ferran Muiños,Radhakrishnan Sabarinathan,Josep M. Piulats,Aura Muntasell,Rodrigo Dienstmann,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Abel Gonzalez-Perez +9 more
TL;DR: A comprehensive landscape of the characteristics of solid tumors that may influence (or be influenced by) the characteristicsof their immune infiltrate is provided to help interpret the response of solid tumor to immunotherapies and guide the development of novel drug combination strategies.